2 Minute Drill
Around the Practice
Between The Lines
Case Based Peer Perspective
DermView
Editorial Board News
Expert Interviews
Expert Perspectives
Fellows Face Off
Frontline Forum
Inside the Clinic
Medical World News
Patient Perspectives
Podcasts
Readout360
Recognize and Refer
Viewpoints
Webinars
Comments on the Epsolay FDA Approval for Rosacea
Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.
Julie Harper, MD, of the Dermatology and Skin Care Center of Birmingham, Alabama, sits down to talk the approval of the 5% encapsulated benzoyl peroxide (E-BPO) cream (Epsolay; Sol-Gel Technologies Ltd and Galderma) that was just recently approved for the treatment of inflammatory lesions of rosacea (papulopustular rosacea or PPR) in adult patients.
This long awaited drug approval is the first rosacea drug approved this year and Harper talks how it works, its potential as a first line treatment, and much more in this interview.
Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls
Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma
In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety
Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea
Survey Finds That Laser Treatments Are Often Not Covered By Insurance
DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment
Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls
Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma
In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety
Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea
Survey Finds That Laser Treatments Are Often Not Covered By Insurance
DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment
Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls
Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma
In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety
Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea
Survey Finds That Laser Treatments Are Often Not Covered By Insurance
DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment
Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls
Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma
In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety
Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea
Survey Finds That Laser Treatments Are Often Not Covered By Insurance
DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment